Campylobacter Jejuni

• USES: Aids in temporary relief of symptoms including •irregular bowel habits, •diarrhea, • constipation, • abdominal pain, •bloating, •nausea, •itching of the anus and •fatigue.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.ICD-10: K59.00, R11.2

DIRECTIONS: • Adults: 2 to 3 sprays orally, three times daily. Children under twelve one half adult dosage. • Do not take within 15 minutes of consuming food, beverage or brushing teeth. • Consult a physician for use in children under 12 years of age.

If pregnant or breast-feeding, ask a health professional before use. In case of overdose, get medical help or contact a Poison Control Center right away. If condition worsens, seek medical attention. KEEP OUT OF REACH OF CHILDREN Do not use if tamper evident seal is broken or missing. Store in a cool place after opening

Recent PubMed references pinned to Campylobacter Jejuni as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• The Campylobacter jejuni flagellar V-ring discerns viscosity levels to alter swimming velocity, metabolic gene expression, and fitness.
  Proceedings of the National Academy of Sciences of the United States of America · 2026 · Ribardo DA, Singh NK, Beeby M, et al.
  PMID 42263120DOI 10.1073/pnas.2603105123
• Sources of Human Campylobacteriosis Cases in Estonia and the Genomic Associations with Broiler Chicken Meat Isolates.
  Pathogens (Basel, Switzerland) · 2026 · Ivanov I, Takkinen HK, Takkinen J, et al.
  PMID 42198665DOI 10.3390/pathogens15050539
• Serine protease HtrA promotes Campylobacter jejuni intestinal colonization through degrading antimicrobial peptide LL-37.
  Science advances · 2026 · Li X, Zhang M, Xu Z, et al.
  PMID 42160414DOI 10.1126/sciadv.aee1996
• Geographic clustering and population structures of Campylobacter jejuni and Campylobacter coli in South and Southeast Asian poultry systems.
  Microbial genomics · 2026 · Lehri B, Nhung LTH, Ghosh K, et al.
  PMID 42096272DOI 10.1099/mgen.0.001706
• Quantitative microbial risk assessment of hyperaerotolerant and multidrug-resistant Campylobacter jejuni and C. coli related to contaminated chicken meat consumption.
  Food research international (Ottawa, Ont.) · 2026 · Chong KH, Mahyudin NA, Hasan H, et al.
  PMID 42083157DOI 10.1016/j.foodres.2026.118980
• Impact of Encapsulated Iron Availability on the Growth Kinetics of Campylobacter jejuni.
  Pathogens (Basel, Switzerland) · 2026 · Olson EG, Matiak EA, Jendza JA, et al.
  PMID 42075726DOI 10.3390/pathogens15040400
• Identification of a core set of Campylobacter jejuni flagella modification genes and a reversible non-motile maf3 phenotype.
  Microbiology (Reading, England) · 2026 · Munjoma L, Bayliss CD
  PMID 42048240DOI 10.1099/mic.0.001698
• Psychrotolerant spoilage bacteria enhanced Campylobacter jejuni culturability on refrigerated chicken meat.
  Food microbiology · 2026 · Yan R, Watson SC, Wei X, et al.
  PMID 41963066DOI 10.1016/j.fm.2026.105051

The 10 most recently updated of 10 ClinicalTrials.gov registrations naming Campylobacter Jejuni as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Safety and Immunogenicity of CJCV2 With and Without ALFQ
  Completed · Phase 1 · Interventional · 59 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT05500417updated 2026-04-01
• LMN-101 in a Campylobacter Human Challenge Model
  Completed · Phase 2 · Interventional · 42 enrolled · Lumen Bioscience, Inc.
  NCT04182490updated 2025-09-25
• CampETEC Hyperimmune Bovine Colostrum (HBC)
  Completed · Phase 1 · Interventional · 27 enrolled · Johns Hopkins Bloomberg School of Public Health
  NCT06122870updated 2025-08-22
• Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
  Completed · Phase 1 · Interventional · 21 enrolled · Lumen Bioscience, Inc.
  NCT04098263updated 2025-02-04
• Efficacy of Rifaximin in Preventing Campylobacteriosis
  Completed · Phase 2 · Phase 3 · Interventional · 30 enrolled · Johns Hopkins Bloomberg School of Public Health
  NCT02280044updated 2018-11-20
• Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
  Completed · Phase 1 · Interventional · 48 enrolled · U.S. Army Medical Research and Development Command
  NCT02067676updated 2018-02-23
• Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota
  Unknown · Observational · 450 enrolled · University of Nottingham
  NCT02040922updated 2017-05-04
• Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection
  Unknown · Phase 1 · Interventional · 16 enrolled · University of Vermont
  NCT01048112updated 2010-01-13
• ACE393-103 Vaccination Challenge Study
  Unknown · Phase 2 · Interventional · 72 enrolled · TD Vaccines A/S
  NCT00859716updated 2009-03-11
• Campylobacter Jejuni Challenge Model Development: Dose Ranging Study
  Unknown · Phase 1 · Interventional · 50 enrolled · University of Vermont
  NCT00434798updated 2008-06-05

Frequently asked questions

What is Campylobacter Jejuni used for?

According to FDA labeling, Campylobacter Jejuni carries indications including: USES: Aids in temporary relief of symptoms including •irregular bowel habits, •diarrhea, • constipation, • abdominal pain, •bloating, •nausea, •itching of the anus and •fatigue.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.